Personalis Publishes PREDICT-DNA Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PSNL?
Source: Newsfilter
- Significant Findings: The PREDICT-DNA study published in the Journal of Clinical Oncology demonstrates that NeXT Personal's ultrasensitive ctDNA testing outperforms current standard methods in predicting outcomes for patients undergoing neoadjuvant therapy, involving 227 patients with Triple-Negative and HER2+ breast cancer.
- Strong Prognostic Power: The study reveals that patients with detectable ctDNA post-NAT have a 4 to 9 times higher likelihood of relapse, with ctDNA status identified as the most significant independent prognostic signal in multivariate analyses, surpassing traditional metrics like nodal status and tumor grade.
- Low-Risk Identification: Findings indicate that ctDNA-negative patients post-NAT exhibit excellent outcomes regardless of pCR status, underscoring NeXT Personal's potential for early clinical intervention.
- Clinical Application Prospects: The results support NeXT Personal's ultrasensitive detection capabilities, which may drive reimbursement expansion in neoadjuvant monitoring, aiding patients in understanding their treatment responses and informing subsequent therapy decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.310
Low
10.00
Averages
11.17
High
12.00
Current: 8.310
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Personalis Publishes PREDICT-DNA Study Results
- Significant Findings: The PREDICT-DNA study published in the Journal of Clinical Oncology demonstrates that NeXT Personal's ultrasensitive ctDNA testing outperforms current standard methods in predicting outcomes for patients undergoing neoadjuvant therapy, involving 227 patients with Triple-Negative and HER2+ breast cancer.
- Strong Prognostic Power: The study reveals that patients with detectable ctDNA post-NAT have a 4 to 9 times higher likelihood of relapse, with ctDNA status identified as the most significant independent prognostic signal in multivariate analyses, surpassing traditional metrics like nodal status and tumor grade.
- Low-Risk Identification: Findings indicate that ctDNA-negative patients post-NAT exhibit excellent outcomes regardless of pCR status, underscoring NeXT Personal's potential for early clinical intervention.
- Clinical Application Prospects: The results support NeXT Personal's ultrasensitive detection capabilities, which may drive reimbursement expansion in neoadjuvant monitoring, aiding patients in understanding their treatment responses and informing subsequent therapy decisions.
See More
Lightspeed Acquires Significant Stake in Kodiak AI
- Stake Acquisition: Lightspeed Management Company purchased 7,340,475 shares of Kodiak AI in Q4 2026 for approximately $80.16 million, representing 5.74% of the fund's 13F reportable AUM, indicating strong conviction in the company's future prospects.
- Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, reflecting a 5.66% increase since its public debut in September 2025, outperforming the S&P 500 by 1.51 percentage points during the same period, showcasing market confidence in its growth.
- Company Overview: Kodiak AI specializes in autonomous driving solutions for commercial and defense applications, leveraging a proprietary multi-sensor architecture to deliver scalable AI navigation in complex environments, targeting commercial transport, defense contractors, and industrial fleet operators.
- Investment Outlook: Despite being a smaller player in the self-driving sector, Kodiak AI has garnered industry attention, with Northland naming it a top pick for 2026 with a price target of $17, reflecting expectations for significant growth potential in the autonomous trucking industry.
See More
Lightspeed Acquires Shares of Kodiak AI
- New Investment Move: Lightspeed acquired 7,340,475 shares of Kodiak AI in Q4 2026, with an estimated transaction value of $80.16 million, reflecting strong confidence in the company, especially given its public listing just six months prior.
- Asset Management Shift: This transaction increased Lightspeed's 13F reportable assets under management (AUM) by 5.74%, highlighting its commitment to Kodiak AI and enhancing its market position in the autonomous driving sector.
- Strong Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, up 5.66% since its September 2025 IPO, outperforming the S&P 500 by 1.51 percentage points, indicating its appeal in a competitive market.
- Industry Outlook Analysis: Kodiak AI focuses on autonomous driving solutions for commercial and defense applications, and while it is a relatively small player, its long-term success will largely depend on the development of the autonomous trucking industry, particularly the adoption of the 'Driving as a Service' model.
See More
Personalis, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Clinical Test Growth: In Q4 2025, Personalis delivered 6,183 clinical tests, representing a 41% sequential growth over Q3 2025 and a 329% year-over-year increase, demonstrating the company's leadership in ultrasensitive MRD testing and robust market demand recovery.
- Revenue and Outlook: The company reported $17.3 million in revenue for Q4, a modest 3% year-over-year increase, while projecting total revenue for 2026 to reach between $78 million and $80 million, reflecting confidence in future growth and strategic market expansion.
- Strategic Expansion: The partnership with Tempus has been strengthened with new coverage for colorectal cancer, and clinical test volumes are expected to reach 43,000 to 45,000 in 2026, indicating a year-over-year growth rate of approximately 170%, which will further solidify market share.
- Financial Health: At the end of 2025, cash and short-term investments totaled $240 million, and while a net loss of approximately $105 million is anticipated for 2026, the company maintains strong cash flow to support future R&D and market expansion.
See More
Personalis (PSNL) Q4 2025 Earnings Call Transcript
See More
Personalis Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Personalis reported a Q4 GAAP EPS of -$0.26, beating expectations by $0.03, indicating an improvement in financial performance despite remaining in the red.
- Revenue Growth: Q4 revenue reached $17.35 million, up 3.3% year-over-year, exceeding market expectations by $0.23 million, demonstrating enhanced competitiveness in the market.
- Surge in Clinical Tests: Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests, with a nearly 400% increase for the full year to 16,233 tests, reflecting strong demand for clinical services.
- Future Guidance: Full-year 2026 revenue guidance is set at $78 to $80 million, below the consensus of $81.68 million, although clinical revenue is expected to grow approximately 5x, indicating a cautious outlook on future growth.
See More
Personalis Publishes PREDICT-DNA Study Results
- Significant Findings: The PREDICT-DNA study published in the Journal of Clinical Oncology demonstrates that NeXT Personal's ultrasensitive ctDNA testing outperforms current standard methods in predicting outcomes for patients undergoing neoadjuvant therapy, involving 227 patients with Triple-Negative and HER2+ breast cancer.
- Strong Prognostic Power: The study reveals that patients with detectable ctDNA post-NAT have a 4 to 9 times higher likelihood of relapse, with ctDNA status identified as the most significant independent prognostic signal in multivariate analyses, surpassing traditional metrics like nodal status and tumor grade.
- Low-Risk Identification: Findings indicate that ctDNA-negative patients post-NAT exhibit excellent outcomes regardless of pCR status, underscoring NeXT Personal's potential for early clinical intervention.
- Clinical Application Prospects: The results support NeXT Personal's ultrasensitive detection capabilities, which may drive reimbursement expansion in neoadjuvant monitoring, aiding patients in understanding their treatment responses and informing subsequent therapy decisions.
See More
Lightspeed Acquires Significant Stake in Kodiak AI
- Stake Acquisition: Lightspeed Management Company purchased 7,340,475 shares of Kodiak AI in Q4 2026 for approximately $80.16 million, representing 5.74% of the fund's 13F reportable AUM, indicating strong conviction in the company's future prospects.
- Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, reflecting a 5.66% increase since its public debut in September 2025, outperforming the S&P 500 by 1.51 percentage points during the same period, showcasing market confidence in its growth.
- Company Overview: Kodiak AI specializes in autonomous driving solutions for commercial and defense applications, leveraging a proprietary multi-sensor architecture to deliver scalable AI navigation in complex environments, targeting commercial transport, defense contractors, and industrial fleet operators.
- Investment Outlook: Despite being a smaller player in the self-driving sector, Kodiak AI has garnered industry attention, with Northland naming it a top pick for 2026 with a price target of $17, reflecting expectations for significant growth potential in the autonomous trucking industry.
See More
Lightspeed Acquires Shares of Kodiak AI
- New Investment Move: Lightspeed acquired 7,340,475 shares of Kodiak AI in Q4 2026, with an estimated transaction value of $80.16 million, reflecting strong confidence in the company, especially given its public listing just six months prior.
- Asset Management Shift: This transaction increased Lightspeed's 13F reportable assets under management (AUM) by 5.74%, highlighting its commitment to Kodiak AI and enhancing its market position in the autonomous driving sector.
- Strong Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, up 5.66% since its September 2025 IPO, outperforming the S&P 500 by 1.51 percentage points, indicating its appeal in a competitive market.
- Industry Outlook Analysis: Kodiak AI focuses on autonomous driving solutions for commercial and defense applications, and while it is a relatively small player, its long-term success will largely depend on the development of the autonomous trucking industry, particularly the adoption of the 'Driving as a Service' model.
See More
Personalis, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Clinical Test Growth: In Q4 2025, Personalis delivered 6,183 clinical tests, representing a 41% sequential growth over Q3 2025 and a 329% year-over-year increase, demonstrating the company's leadership in ultrasensitive MRD testing and robust market demand recovery.
- Revenue and Outlook: The company reported $17.3 million in revenue for Q4, a modest 3% year-over-year increase, while projecting total revenue for 2026 to reach between $78 million and $80 million, reflecting confidence in future growth and strategic market expansion.
- Strategic Expansion: The partnership with Tempus has been strengthened with new coverage for colorectal cancer, and clinical test volumes are expected to reach 43,000 to 45,000 in 2026, indicating a year-over-year growth rate of approximately 170%, which will further solidify market share.
- Financial Health: At the end of 2025, cash and short-term investments totaled $240 million, and while a net loss of approximately $105 million is anticipated for 2026, the company maintains strong cash flow to support future R&D and market expansion.
See More
Personalis (PSNL) Q4 2025 Earnings Call Transcript
See More
Personalis Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Personalis reported a Q4 GAAP EPS of -$0.26, beating expectations by $0.03, indicating an improvement in financial performance despite remaining in the red.
- Revenue Growth: Q4 revenue reached $17.35 million, up 3.3% year-over-year, exceeding market expectations by $0.23 million, demonstrating enhanced competitiveness in the market.
- Surge in Clinical Tests: Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests, with a nearly 400% increase for the full year to 16,233 tests, reflecting strong demand for clinical services.
- Future Guidance: Full-year 2026 revenue guidance is set at $78 to $80 million, below the consensus of $81.68 million, although clinical revenue is expected to grow approximately 5x, indicating a cautious outlook on future growth.
See More
